SCHEMBL2164111

SCHEMBL2164111

CCOc1cc2nnnc(Nc3ccc(C)cc3)c2cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.55
EGFR P00533 11/20 0.51
KDR P35968 8/20 0.50
LCK P06239 3/20 0.48
SRC P12931 1/20 0.48
RET P07949 2/20 0.47
FLT1 P17948 1/20 0.47
GAK O14976 1/20 0.47
RIPK2 O43353 1/20 0.47
STK10 O94804 1/20 0.47
FLT3 P36888 1/20 0.47
JAK3 P52333 1/20 0.47
AAK1 Q2M2I8 1/20 0.47
Q6ZSR9 Q6ZSR9 1/20 0.47
SLK Q9H2G2 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
RPS6KA6 Q9UK32 1/20 0.47
ALK Q9UM73 1/20 0.47
TP53 P04637 1/20 0.47
CLK1 P49759 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2164453 0.90 KDR (0.53) SLC2A1EGFRKDRLCKSRC
SCHEMBL2163779 0.89 KDR (0.61) EGFRKDRLCKSRCFLT1
SCHEMBL2165397 0.89 EGFR (0.60) EGFRKDRLCKSRCRET
SCHEMBL2165852 0.89 EGFR (0.54) SLC2A1EGFRKDRLCKSRC
SCHEMBL2163570 0.87 SLC2A1 (0.52) SLC2A1EGFRKDRLCKFLT1
SCHEMBL2165634 0.86 EGFR (0.54) EGFRKDRLCKSRCGAK
SCHEMBL2163808 0.85 EPHA2 (0.57) EGFRKDRFLT1
SCHEMBL2165975 0.85 EGFR (0.48) EGFRKDRLCKSRCRET
SCHEMBL2164488 0.83 SRC (0.51) EGFRKDRLCKSRCFLT1
SCHEMBL2164413 0.83 EGFR (0.53) EGFRKDRLCKSRCRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US claimed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 SLC2A1 1656/4885EGFR 8/4885KDR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.